Effect of comorbidities and medications on left ventricular mass regression after bariatric surgery

Journal of Clinical Hypertension

Volumn 12, Issue 3, 2010, Pages 223-227

  Syed, Mohsin ^a   Torosoff, Mikhail ^b   Rosati, Carl ^b   Alger, Sharon ^b   Fein, Steven ^b  

^a Holy Rosary Medical Center   (United States)

^b ALBANY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ARTICLE; BARIATRIC SURGERY; BLOOD PRESSURE REGULATION; BLOOD PRESSURE VARIABILITY; BODY MASS; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MALE; OBESITY; PRIORITY JOURNAL; WEIGHT REDUCTION;

ANTIHYPERTENSIVE AGENTS; BARIATRIC SURGERY; BLOOD PRESSURE; BODY MASS INDEX; CARDIAC VOLUME; COMORBIDITY; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; WEIGHT LOSS;

EID: 77950174333     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2009.00233.x     Document Type: Article

References (21)

1. Rosamond W, Flegal K, Furie K. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008, 117:e25-e146.
2. Bell DS. Diabetes: a cardiac condition manifesting as hyperglycemia. Endocr Pract 2008, 14:924-932.
3. Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993, 11:309-317.
4. de Simone G, Olsen MH, Wachtell K. Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study. J Hum Hypertens 2007, 21:625-632.
5. Devereux RB, Dahlof B, Gerdts E. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004, 110:1456-1462.
6. Aepfelbacher FC, Yeon SB, Weinrauch LA. Improved glycemic control induces regression of left ventricular mass in patients with type 1 diabetes mellitus. Int J Cardiol 2004, 94:47-51.
7. Barrios V, Escobar C, Calderon A. Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice. The VIPE study. J Renin Angiotensin Aldosterone Syst 2006, 7:236-242.
8. Ashrafian H, le Roux CW, Darzi A. Effects of bariatric surgery on cardiovascular function. Circulation 2008, 118:2091-2102.
9. Syed M, Rosati C, Torosoff MT. The impact of weight loss on cardiac structure and function in obese patients. Obesity Surgery 2009, 19:36.
10. Fleiss JL. Statistical Methods for Rates and Proportions 1982, 2nd ed, New York, NY, John Wiley
11. Reichek N, Devereux R. Left ventricular hypertrophy: relationship of anatomic, echocardiographic and electrocardiographic findings. Circulation 1981, 63:1391.
12. Devereux RB, Reichek N. Repolarization abnormalities of left ventricular hypertrophy. Clinical, echocardiographic and hemodynamic correlates. J Electrocardiol 1982, 15:47.
13. Devereux RB, Savage DD, Drayer JIM. Left ventricular hypertrophy and function in high, normal and low renin forms of essential hypertension. Hypertension 1982, 4:524.
14. Devereux RB, Philips MC, Casale PN. Geometric determinants of electrocardiographic left ventricular hypertrophy. Circulations 1983, 67:907.
15. Troy BL, Pombo J, Rackley CE. Measurement of left ventricular wall thickness and mass by echocardiography. Circulation 1972, 45:602-611.
16. Messerli FH, Sundgaard-Riise K, Reisin ED. Dimorphic cardiac adaptation to obesity and arterial hypertension. Ann Intern Med 1983, 99:757-761.
17. Chobanian AV, Bakris GL, Black HR. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003, 42:1206-1252.
18. Gosse P, Roudaut R, Herrero G. Beta-blockers vs. angiotensin-converting enzyme inhibitors in hypertension: effects on left ventricular hypertrophy. J Cardiovasc Pharmacol 1990, 16(suppl 5):S145-S150.
19. Mansia G, De Backer G, Dominiczak A. 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press 2007, 16:135-232.
20. Messerli FH, Beevers DG, Franklin SS. beta-Blockers in hypertension-the emperor has no clothes: an open letter to present and prospective drafters of new guidelines for the treatment of hypertension. Am J Hypertens 2003, 16:870-873.
21. Thomas GN, Tomlinson B. Prevention of macrovascular disease in type 2 diabetic patients: blockade of the Renin-Angiotensin-aldosterone system. Curr Diabetes Rev 2008, 4:63-78.